HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Y Uemura Selected Research

cycloprodigiosin

10/2000Cycloprodigiosin hydrochloride, H(+)/CL(-) symporter, induces apoptosis and differentiation in HL-60 cells.
4/2000Cycloprodigiosin hydrochloride, a H+/Cl- symporter, induces apoptosis in human breast cancer cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Y Uemura Research Topics

Disease

5Neoplasms (Cancer)
05/2001 - 06/2000
4Breast Neoplasms (Breast Cancer)
04/2001 - 04/2000
3Carcinoma (Carcinomatosis)
04/2019 - 09/2000
3Neoplasm Metastasis (Metastasis)
01/2007 - 06/2000
2Esophageal Neoplasms (Esophageal Cancer)
01/2007 - 06/2000
2Ovarian Neoplasms (Ovarian Cancer)
05/2001 - 01/2000
1Inflammation (Inflammations)
04/2019
1Abscess
09/2017
1Cysts
09/2017
1Leukocytosis (Pleocytosis)
02/2009
1Leukemoid Reaction
02/2009
1Chronic Neutrophilic Leukemia
02/2009
1Ethmoid Sinusitis
06/2007
1Infections
06/2007
1Sinusitis
06/2007
1Lymphoma (Lymphomas)
06/2007
1Leprosy (Hansen's Disease)
07/2005
1Tuberculoid Leprosy
07/2005
1Granuloma
05/2004
1Sarcoidosis (Schaumann Disease)
05/2004
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
06/2001
1Adenocarcinoma
05/2001
1Mucinous Adenocarcinoma (Mucinous Carcinoma)
05/2001
1Retinal Degeneration
12/2000
1Retinitis Pigmentosa (Pigmentary Retinopathy)
12/2000
1Liver Neoplasms (Liver Cancer)
10/2000
1Leukemia
10/2000
1Proctitis
09/2000
1Paraneoplastic Syndromes (Paraneoplastic Syndrome)
09/2000
1Squamous Cell Neoplasms (Squamous Cell Cancer)
07/2000
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
07/2000

Drug/Important Bio-Agent (IBA)

2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
02/2009 - 09/2000
2Estrogen ReceptorsIBA
04/2001 - 08/2000
2Antineoplastic Agents (Antineoplastics)IBA
04/2001 - 01/2000
2cycloprodigiosinIBA
10/2000 - 04/2000
2hydrogen-chloride symporterIBA
10/2000 - 04/2000
1Capsules (Microcapsules)IBA
09/2017
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
02/2009
1CytokinesIBA
02/2009
1Alkaline PhosphataseIBA
02/2009
1AntigensIBA
07/2005
1Interleukin-12 Receptors (Interleukin 12 Receptor)IBA
07/2005
1Interleukin-12 (IL 12)IBA
07/2005
1Interferon-gamma (Interferon, gamma)IBA
05/2004
1InterleukinsIBA
05/2004
1Monoclonal AntibodiesIBA
05/2004
1EpitopesIBA
06/2001
1Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA
06/2001
1CollagenIBA
05/2001
1Collagen Type IV (Type IV Collagen)IBA
05/2001
1Hormones (Hormone)IBA
04/2001
1ResveratrolIBA
04/2001
1Linoleic Acid (Linoleate)IBA
04/2001
1Caspase 3 (Caspase-3)IBA
12/2000
1Methylnitrosourea (N-Methyl-N-nitrosourea)IBA
12/2000
1Retinaldehyde (Retinal)IBA
12/2000
1Sulfasalazine (Azulfidine)FDA LinkGeneric
09/2000
1Suppositories (Vaginal Suppositories)IBA
09/2000
1Parathyroid Hormone-Related ProteinIBA
09/2000
1Phenobarbital (Luminal)FDA Link
08/2000
1Eicosapentaenoic AcidIBA
08/2000
1Fish OilsIBA
08/2000
1GenisteinIBA
08/2000
1IsoflavonesIBA
08/2000
1Indicators and Reagents (Reagents)IBA
07/2000
1SerpinsIBA
07/2000
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2000
1squamous cell carcinoma-related antigenIBA
07/2000
1Tumor Biomarkers (Tumor Markers)IBA
07/2000
1Peptide Hydrolases (Proteases)FDA Link
07/2000
1Topoisomerase InhibitorsIBA
01/2000
1Cisplatin (Platino)FDA LinkGeneric
01/2000
1Telomerase (Telomerase Reverse Transcriptase)IBA
01/2000
12- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
01/2000
1Alkylating AgentsIBA
01/2000
1telomerase RNA (bTR)IBA
01/2000

Therapy/Procedure

3Esophagectomy
04/2019 - 06/2000
2Radiotherapy
01/2003 - 06/2000
1Chemoradiotherapy
04/2019
1Hematopoietic Stem Cell Transplantation
06/2007
1Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
06/2007